Generic Biologics Will Not Be Approved For At Least Three Years – Barr CEO
Generic biologics are not likely to be introduced in the U.S. for at least three years, Barr CEO Bruce Downey told the Banc of America Health Care Conference May 20
You may also be interested in...
FDA's upcoming draft guidance on follow-on biologics will allow use of data that are in the public domain only, Center for Drug Evaluation & Research acting Director Steven Galson, MD, told the Schwab Soundview Washington Research Group health care conference May 5
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials